Radiolabelled peptides in the diagnosis and therapy of tumours
Authors:
J. Cihlo; M. Lázníček
Authors‘ workplace:
Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové, katedra farmakologie a toxikologie
Published in:
Čes. slov. Farm., 2008; 57, 70-77
Category:
Review Articles
Overview
In the last two decades, radiolabelled receptor-specific peptides have profiled themselves as excellent tools that have expressively increased the diagnostic and therapeutical possibilities of tumours predominantly of neuroendocrine origin. The aim of this review paper is to transparently inform the Czech scientific fraternity about the significance and limitations of the use of this group of radiopharmaceuticals in clinical practice.
Key words:
radiopharmaceuticals – diagnosis – therapy – cancers – receptor-specific peptides
Sources
1. Reubi, J. C.: Endocr. Rev., 2003; 24, 389–427.
2. de Herder, W. W., Lamberts, S. W.: Curr. Opin. Oncol., 2002; 14, 53–57.
3. Lamberts, S. W., de Herder, W. W., Hofland, L. J.: Trends Endocrinol. Metab., 2002; 13, 451–457.
4. Behr, T. M., Behe, M., Becker, W.: Q. J. Nucl. Med., 1999; 43, 268–280.
5. de Visser, M., Janssen, P. J., Srinivasan, A. et al.: Eur. J. Nucl. Med. Mol. Imaging, 2003; 30, 1134–1139.
6. Koikov, L. N., Ebetino, F. H., Solinsky, M. G. et al.: Bioorg. Med. Chem. Lett., 2003; 13, 2647–2650.
7. Reubi, J. C., Waser, B., Schaer, J. C., Laissue, J. A.: Eur. J. Nucl. Med., 2001; 28, 836–846.
8. Weiner, R. E.,Thakur, M. L.: BioDrugs, 2005; 19, 145–163.
9. Breeman, W. A., Kwekkeboom, D. J., de Blois, E. et al.: Anticancer Agents Med. Chem., 2007; 7, 345–357.
10. Patel, Y. C., Greenwood, M. T., Panetta, R. et al.: Life Sci., 1995; 57, 1249–1265.
11. Scherubl, H., Hescheler, J.,Riecken, E. O.: Horm. Metab. Res. Suppl., 1993; 27, 1–4.
12. Reubi, J. C.: Neuroendocrinology, 2004; 80 (Suppl. 1), 51–56.
13. Blok, D., Feitsma, R. I., Vermeij, P., Pauwels, E. J.: Eur. J. Nucl. Med., 1999; 26, 1511–1519.
14. Hejna, M., Schmidinger, M., Raderer, M.: Ann. Oncol., 2002; 13, 653–668.
15. Gotthardt, M., Boermann, O. C., Behr, T. M. et al.: Curr. Pharm. Des., 2004; 10, 2951–2963.
16. Breeman, W. A., de Jong, M., Kwekkeboom, D. J. et al.: Eur. J. Nucl. Med., 2001; 28, 1421–1429.
17. Wild, D., Schmitt, J. S., Ginj, M. et al.: Eur. J. Nucl. Med. Mol. Imaging, 2003; 30, 1338–1347.
18. Virgolini, I., Traub, T., Novotny, C. et al.: Curr. Pharm. Des., 2002; 8, 1781–1807.
19. Decristoforo, C., Maina, T., Nock, B. et al.: Eur. J. Nucl. Med. Mol. Imaging, 2003; 30, 1211–1219.
20. Kopecky, M., Trejtnar, F., Laznicek, M. et al.: Nucl. Med. Commun., 2005; 26, 549–554.
21. Maina, T., Nock, B., Nikolopoulou, A. et al.: Eur. J. Nucl. Med. Mol. Imaging, 2002; 29, 742–753.
22. Maina, T., Nock, B. A., Cordopatis, P. et al.: Eur. J. Nucl. Med. Mo. Imaging, 2006; 33, 831–840.
23. Decristoforo, C., Mather, S. J., Cholewinski, W. et al.: Eur. J. Nucl. Med., 2000; 27, 1318–1325.
24. Decristoforo, C., Melendez-Alafort, L., Sosabowski, J. K., Mather, S. J.: J. Nucl. Med., 2000; 41, 1114–1119.
25. Cremonesi, M., Ferrari, M., Bodei, L. et al.: J. Nucl. Med., 2006; 47, 1467–1475.
26. de Jong, M., Breeman, W. A., Bernard, B. F. et al.: Int. J. Cancer, 2001; 92, 628–633.
27. Lewis, J. S., Wang, M., Laforest, R. et al.: Int. J. Cancer, 2001; 94, 873–877.
28. Bugaj, J. E., Erion, J. L., Johnson, M. A. et al.: Nucl. Med. Biol., 2001; 28, 327–334.
29. Cyr, J. E., Pearson, D. A., Wilson, D. M. et al.: J. Med. Chem., 2007; 50, 1354–1364.
30. Lewis, J. S., Lewis, M. R., Cutler, P. D. et al.: Clin. Cancer Res., 1999; 5, 3608–3616.
31. Lewis, J. S., Srinivasan, A., Schmidt, M. A., Anderson, C. J.: Nucl. Med. Biol., 1999; 26, 267–273.
32. Blower, P.: Dalton Trans, 2006; 1705–1711.
33. Lister-James, J., Moyer, B. R.,Dean, R. T.: Q. J. Nucl. Med., 1997; 41, 111–118.
34. Kaltsas, G. A., Papadogias, D., Makras, P., Grossman, A. B.: Endocr. Relat. Cancer, 2005; 12, 683–699.
35. Caplin, M. E., Buscombe, J. R., Hilson, A. J. et al.: Lancet, 1998; 352, 799–805.
36. Gibril, F., Reynolds, J. C., Doppman, J. L. et al.: Ann. Intern. Med., 1996; 125, 26–34.
37. Cremonesi, M., Ferrari, M., Bodei, L. et al.: Q. J. Nucl. Med. Mol. Imaging, 2006; 50, 288–295.
38. Forrer, F., Valkema, R., Kwekkeboom, D. J. et al.: Best. Pract. Res. Clin. Endocrinol. Metab, 2007; 21, 111–129.
39. Teunissen, J. J., Kwekkeboom, D. J., de Jong, M. et al.: Best. Pract. Res. Clin. Gastroenterol., 2005; 19, 595–616.
40. Capello, A., Krenning, E. P., Breeman, W. A. et al.: J. Nucl. Med., 2003; 44, 98–104.
41. de Jong, M., Bakker, W. H., Krenning, E. P. et al.: Eur. J. Nucl. Med., 1997; 24, 368–371.
42. Krenning, E. P., de Jong, M., Kooij, P. P. et al.: Ann. Oncol., 1999; 10 (Suppl. 2), S23–S29.
43. Anderson, C. J., Dehdashti, F., Cutler, P. D. et al.: J. Nucl. Med., 2001; 42, 213–221.
44. Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P. et al.: Eur. J. Nucl. Med., 2001; 28, 1319–1325.
45. Deutsch, E., Libson, K., Vanderheyden, J. L. et al.: Int. J. Rad. Appl. Instrum. B, 1986; 13, 465–477.
46. Cremonesi, M., Ferrari, M., Zoboli, S. et al.: Eur. J. Nucl. Med., 1999; 26, 877–886.
47. Pauwels, S., Barone, R., Walrand, S. et al.: J. Nucl. Med., 2005; 46 (Suppl. 1), 92S–98S.
48. Engstrom, P. F., Lavin, P. T., Moertel, C. G. et al.: J. Clin. Oncol., 1984; 2, 1255–1259.
49. Bodei, L., Cremonesi, M., Zoboli, S. et al.: Eur. J. Nucl. Med. Mol. Imaging, 2003; 30, 207–216.
50. Barone, R., Borson-Chazot, F., Valkema, R. et al.: J. Nucl. Med., 2005; 46 (Suppl. 1), 99S–106S.
51. Rolleman, E. J., Valkema, R., de Jong, M. et al.: Eur. J. Nucl. Med. Mol. Imaging, 2003; 30, 9–15.
52. van Eerd, J. E., Vegt, E., Wetzels, J. F. et al.: J. Nucl. Med., 2006; 47, 528–533.
53. Vegt, E., Wetzels, J. F., Russel, F. G. et al.: J. Nucl. Med., 2006; 47, 432–436.
54. Behe, M., Kluge, G., Becker, W. et al.: J. Nucl. Med., 2005; 46, 1012–1015.
55. Gotthardt, M., van Eerd-Vismale, J., Oyen, W. J. et al.: J. Nucl. Med., 2007; 48, 596–601.
56. Barone, R., Van Der Smissen, P., Devuyst, O. et al.: Kidney Int., 2005; 67, 969–976.
57. de Jong, M., Barone, R., Krenning, E. et al.: J. Nucl. Med., 2005; 46, 1696–1700.
58. Melis, M., Krenning, E. P., Bernard, B. F. et al.: Eur. J. Nucl. Med. Mol. Imaging, 2005; 32, 1136–1143.
59. Christensen, E. I., Nielsen, R.: Rev. Physiol. Biochem. Pharmacol., 2007; 158, 1–22.
60. Christensen, E. I.,Verroust, P. J.: Pediatr. Nephrol., 2002; 17, 993–999.
61. Verroust, P. J.,Christensen, E. I.: Nephrol. Dial. Transplant., 2002; 17, 1867–1871.
62. Moestrup, S. K., Cui, S., Vorum, H. et al.: J. Clin. Invest., 1995; 96, 1404–1413.
63. Rolleman, E. J., Forrer, F., Bernard, B. et al.: Eur. J. Nucl. Med. Mol. Imaging, 2007; 34, 763–771.
64. Bodei, L., Cremonesi, M., Grana, C. et al.: Eur. J. Nucl. Med. Mol. Imaging, 2004; 31, 1038–1046.
65. de Jong, M., Valkema, R., Jamar, F. et al.: Semin. Nucl. Med., 2002; 32, 133–140.
66. Reubi, J. C.,Waser, B.: Eur. J. Nucl. Med. Mol. Imaging, 2003; 30, 781–793.
67. Reubi, C., Gugger, M., Waser, B.: Eur. J. Nucl. Med. Mol. Imaging, 2002; 29, 855–862.
68. van Hagen, P. M., Breeman, W. A., Bernard, H. F. et al.: Int. J. Cancer, 2000; 90, 186–198.
69. Schumacher, T., Hofer, S., Eichhorn, K. et al.: Eur. J. Nucl. Med. Mol. Imaging, 2002; 29, 486–493.
Labels
Pharmacy Clinical pharmacologyArticle was published in
Czech and Slovak Pharmacy
2008 Issue 2
Most read in this issue
- Semisynthetic cellulose derivatives as the base of hydrophilic gel systems
- Lactobacilli and their probiotic properties
- Standard prescriptions for the formulation of medicinal preparations in pharmacies I. Suspensions for dermal administration
- Medicinal plants and diabetes mellitus